It is well recognized that early diagnosis and ongoing management of Alzheimer’s Disease (AD) requires a patient-centric, highly coordinated effort among a large multidisciplinary team of clinicians. As such, this proposed initiative establishes meaningful, small group interactions among key stakeholders (neurologists, dementia specialists, geriatricians, geriatric psychologists, radiologists, and primary care clinicians) that will, through a variety of collaborative educational experiences, help all members of the care team consider approaches to reducing barriers to effective coordinated care and encourages each participant to create an action plan to improve the quality of AD care delivered within their organization. Considering the complexity of this challenge, lack of expertise, and the breadth of communication and cooperation required, participants would highly benefit from an educational intervention that includes discussions with knowledgeable experts and peers from within and outside of their own communities who can share experiences, strategies, challenges, and success stories.

CME/CE Accreditation Information

The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.

CME/CE Accreditation Information

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).

CME/CE Accreditation Information

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.

CME/CE Accreditation Information

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information

Multiple myeloma (MM) is a clonal plasma cell disorder arising from the bone marrow and is the second most common hematologic malignancy in the United States (US), with an incidence of approximately 35,000 new cases per year. While progression-free survival (PFS) benefit is often seen with MM therapeutics, overall survival (OS) benefit is rarely seen with novel therapies, and improvements in PFS are still associated with adverse events and long-term disease refractoriness. Over the past few decades, rigorous pre-clinical and clinical research has led to the discovery of novel therapies that have dramatically changed the treatment landscape of MM in the frontline as well as in the relapsed/refractory setting. Despite implementing multimodal approaches to treat MM, the major challenge remains that the vast majority of patients eventually relapse and become refractory to multiple drug classes. Additionally, patients require continuous treatment throughout the disease course, which can negatively affect their quality of life due to potential therapy-related side effects. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with multiple myeloma.

CME/CE Accreditation Information

Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments may help patients live longer, creating unique clinical needs. Adults now make up more than a quarter of patients with SMA. However, there are no specific guidelines for the assessment and treatment of adult patients, leading to gaps in their diagnosis and management. Adult care is complex and requires multidisciplinary care. This collaborative CME provides the opportunity to learn and share best practices that will improve outcomes for patients with SMA.

CME/CE Accreditation Information

Often seen in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), arise as a consequence of immune system involvement and can have myriad health consequences. Both CIDP and MMN are characterized by complex presentations and frequent misdiagnoses. CIDP shows gradual peripheral nerve demyelination, leading to weakness and sensory loss, while MMN presents with asymmetric weakness devoid of sensory complications. With an array of treatment options, managing polyneuropathy in CIDP and MMN can be challenging. This collaborative platform serves as a unifying space for healthcare providers, facilitating the exchange of insights and elevating the standard of care for patients affected by CIDP and MMN. In this learning activity, you will learn how to enhance the lives of CIDP and MMN patients via a program promoting local and cross-community support, driving effective practice-sharing for better outcomes.

CME/CE Accreditation Information